NasdaqGS - Delayed Quote • USD
Ultragenyx Pharmaceutical Inc. (RARE)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 17 | 17 | 19 | 19 |
Avg. Estimate | -1.75 | -1.64 | -6.45 | -5.04 |
Low Estimate | -2.04 | -2.01 | -8.32 | -7.05 |
High Estimate | -1.39 | -1.36 | -5.23 | -1.58 |
Year Ago EPS | -2.33 | -2.25 | -8.25 | -6.45 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 15 | 18 | 19 |
Avg. Estimate | 116.36M | 125.25M | 513.08M | 642.09M |
Low Estimate | 98.8M | 120.38M | 499.73M | 541.73M |
High Estimate | 124.6M | 130.1M | 530.01M | 920.7M |
Year Ago Sales | 100.5M | 108.31M | 434.25M | 513.08M |
Sales Growth (year/est) | 15.80% | 15.60% | 18.20% | 25.10% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -1.98 | -2.07 | -2.08 | -1.62 |
EPS Actual | -2.33 | -2.25 | -2.23 | -1.52 |
Difference | -0.35 | -0.18 | -0.15 | 0.1 |
Surprise % | -17.70% | -8.70% | -7.20% | 6.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -1.75 | -1.64 | -6.45 | -5.04 |
7 Days Ago | -1.76 | -1.64 | -6.45 | -4.97 |
30 Days Ago | -1.76 | -1.63 | -6.44 | -4.96 |
60 Days Ago | -1.76 | -1.63 | -6.43 | -4.79 |
90 Days Ago | -1.65 | -1.58 | -6.21 | -4.36 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 1 | 1 |
Up Last 30 Days | 1 | -- | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
CURRENCY IN USD | RARE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 24.90% | -- | -- | 2.60% |
Next Qtr. | 27.10% | -- | -- | 13.40% |
Current Year | 21.80% | -- | -- | 5.20% |
Next Year | 21.90% | -- | -- | 13.30% |
Next 5 Years (per annum) | 8.90% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | TD Cowen: Buy to Buy | 4/24/2024 |
Initiated | RBC Capital: Outperform | 4/22/2024 |
Reiterates | Wedbush: Neutral to Neutral | 4/17/2024 |
Reiterates | Wedbush: Neutral to Neutral | 4/16/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Maintains | JP Morgan: Overweight to Overweight | 3/18/2024 |
Related Tickers
BPMC Blueprint Medicines Corporation
90.73
-1.66%
AGIO Agios Pharmaceuticals, Inc.
31.67
0.00%
MREO Mereo BioPharma Group plc
2.8100
+1.08%
PTCT PTC Therapeutics, Inc.
25.49
+1.11%
QURE uniQure N.V.
4.5400
-0.44%
PTGX Protagonist Therapeutics, Inc.
24.66
-4.05%
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.89%
INSM Insmed Incorporated
24.92
-3.45%
SAGE Sage Therapeutics, Inc.
13.58
-3.00%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%